Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$5.67 - $8.54 $166,902 - $251,383
-29,436 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$13.4 - $16.3 $36,099 - $43,912
-2,694 Reduced 8.38%
29,436 $406,000
Q2 2021

Aug 10, 2021

SELL
$14.81 - $19.13 $134,326 - $173,509
-9,070 Reduced 22.01%
32,130 $477,000
Q1 2021

May 17, 2021

BUY
$14.52 - $23.53 $16,436 - $26,635
1,132 Added 2.83%
41,200 $733,000
Q4 2020

Feb 12, 2021

BUY
$10.14 - $15.19 $1,338 - $2,005
132 Added 0.33%
40,068 $572,000
Q3 2020

Nov 13, 2020

BUY
$9.57 - $21.32 $32,183 - $71,699
3,363 Added 9.2%
39,936 $404,000
Q2 2020

Aug 05, 2020

SELL
$12.21 - $16.99 $89,670 - $124,774
-7,344 Reduced 16.72%
36,573 $538,000
Q1 2020

May 14, 2020

SELL
$9.03 - $19.72 $33,456 - $73,062
-3,705 Reduced 7.78%
43,917 $587,000
Q4 2019

Feb 13, 2020

BUY
$13.01 - $17.15 $62,942 - $82,971
4,838 Added 11.31%
47,622 $671,000
Q3 2019

Nov 12, 2019

SELL
$14.55 - $20.56 $104,527 - $147,703
-7,184 Reduced 14.38%
42,784 $699,000
Q2 2019

Aug 13, 2019

BUY
$15.0 - $19.62 $749,520 - $980,372
49,968 New
49,968 $784,000
Q1 2019

May 14, 2019

SELL
$11.65 - $17.72 $517,726 - $787,476
-44,440 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$10.72 - $16.73 $50,223 - $78,380
4,685 Added 11.78%
44,440 $495,000
Q3 2018

Nov 14, 2018

BUY
$17.73 - $26.69 $47,498 - $71,502
2,679 Added 7.23%
39,755 $970,000
Q2 2018

Aug 10, 2018

SELL
$10.79 - $24.44 $110,057 - $249,288
-10,200 Reduced 21.58%
37,076 $673,000
Q1 2018

May 14, 2018

SELL
$9.0 - $20.16 $25,101 - $56,226
-2,789 Reduced 5.57%
47,276 $528,000
Q4 2017

Feb 14, 2018

BUY
$13.26 - $22.86 $39,156 - $67,505
2,953 Added 6.27%
50,065 $973,000
Q2 2017

Aug 14, 2017

BUY
N/A
47,112
47,112 $938,000

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $684M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.